Induced pluripotent stem cells from a spinal muscular atrophy patient
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Spinal muscular atrophy is one of the most common inherited forms of neurological disease leading to infant mortality. Patients have selective loss of lower motor neurons resulting in muscle weakness, paralysis and often death. Although patient fibroblasts have been used extensively to study spinal muscular atrophy, motor neurons have a unique anatomy and physiology which may underlie their vulnerability to the disease process. Here we report the generation of induced pluripotent stem cells from skin fibroblast samples taken from a child with spinal muscular atrophy. These cells expanded robustly in culture, maintained the disease genotype and generated motor neurons that showed selective deficits compared to those derived from the child's unaffected mother. This is the first study to show that human induced pluripotent stem cells can be used to model the specific pathology seen in a genetically inherited disease. As such, it represents a promising resource to study disease mechanisms, screen new drug compounds and develop new therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“SMA iPSC-derived motor neurons showed a higher vulnerability with reduced dendritic and axonal length.”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [49]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Technologies to reprogram adult cells back to a pluripotent state, termed induced pluripotent stem cells (iPSCs) (Takahashi and Yamanaka, 2006; Yu et al., 2007), provide an unprecedented platform for studying human genetic disorders (Ebert et al., 2009; Mattis et al., 2015).”
From Modeling Psychomotor Retardation using iPSCs from MCT8-Deficient Patients Indicates a Prominent Role for the Blood-Brain Barrier (2017) · cites this paper as Ebert et al., 2009
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“RNA analysis from SMA iPSC-derived motor neuron demonstrates hyperactivation of the endoplasmic reticulum (ER) stress pathway due to activated unfolded SMN [49].”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [49]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., & Yamanaka, S. (2007) · Cell · doi:10.1016/j.cell.2007.11.019 · Cited by 20,221
Exploration, normalization, and summaries of high density oligonucleotide array probe level data
Irizarry, R. A. (2003) · Biostatistics · doi:10.1093/biostatistics/4.2.249 · Cited by 10,603
Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells
Yu, J., Vodyanik, M. A., Smuga-Otto, K., Antosiewicz-Bourget, J., Frane, J. L., Tian, S., Nie, J., Jonsdottir, G. A., Ruotti, V., Stewart, R., et al. (2007) · Science · doi:10.1126/science.1151526 · Cited by 10,310
Self-citationBolstad, B. M., Irizarry, R. A., Åstrand, M., & Speed, T. P. (2003) · Bioinformatics · doi:10.1093/bioinformatics/19.2.185 · Cited by 8,266
Identification and characterization of a spinal muscular atrophy-determining gene
Lefebvre, S., Bürglen, L., Reboullet, S., Clermont, O., Burlet, P., Viollet, L., Benichou, B., Cruaud, C., Millasseau, P., Zeviani, M., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90460-3 · Cited by 3,990
CNS stem cells express a new class of intermediate filament protein
Lendahl, U., Zimmerman, L. B., & McKay, R. D. G. (1990) · Cell · doi:10.1016/0092-8674(90)90662-x · Cited by 3,151
Pvclust: an R package for assessing the uncertainty in hierarchical clustering
Suzuki, R., & Shimodaira, H. (2006) · Bioinformatics · doi:10.1093/bioinformatics/btl117 · Cited by 2,451
Reprogramming of human somatic cells to pluripotency with defined factors
Park, I.-H., Zhao, R., West, J. A., Yabuuchi, A., Huo, H., Ince, T. A., Lerou, P. H., Lensch, M. W., & Daley, G. Q. (2008) · Nature · doi:10.1038/nature06534 · Cited by 2,436
Disease-Specific Induced Pluripotent Stem Cells.
Park, I.-H., Arora, N., Huo, H., Maherali, N., Ahfeldt, T., Shimamura, A., Lensch, M. W., Cowan, C., Hochedlinger, K., & Daley, G. Q. (2008) · Cell · doi:10.1016/j.cell.2008.07.041 · Cited by 2,196
Neuronal specification in the spinal cord: inductive signals and transcriptional codes
Jessell, T. M. (2000) · Nature Reviews Genetics · doi:10.1038/35049541 · Cited by 2,089
Cited by
Mechanisms underlying inflammation in neurodegeneration
Glass, C. K., Saijo, K., Winner, B., Marchetto, M. C., & Gage, F. H. (2010) · Cell · doi:10.1016/j.cell.2010.02.016 · Cited by 3,580
“The recent demonstration that induced pluripotent stem (iPS) cells derived from ALS patients can be differentiated into astrocytes and specific types of neurons represents an important advance for developing in vitro humanized systems for mechanistic studies and evaluation of therapeutic agents (Dimos et al., 2008; Eb…”
Human induced pluripotent stem cells free of vector and transgene sequences
Yu, J., Hu, K., Smuga-Otto, K., Tian, S., Stewart, R., Slukvin, I. I., & Thomson, J. A. (2009) · Science · doi:10.1126/science.1172482 · Cited by 2,386
Self-citationThe Science of Stroke: Mechanisms in Search of Treatments
Moskowitz, M. A., Lo, E. H., & Iadecola, C. (2010) · Neuron · doi:10.1016/j.neuron.2010.07.002 · Cited by 1,930
Soldner, F., Hockemeyer, D., Beard, C., Gao, Q., Bell, G. W., Cook, E. G., Hargus, G., Blak, A., Cooper, O., Mitalipova, M., et al. (2009) · Cell · doi:10.1016/j.cell.2009.02.013 · Cited by 1,549
“Factor-free hiPSCs Maintain a Pluripotent ESC-like State Although silencing of transgene expression has been reported for several hiPSCs, all hiPSCs generated to date (including the lines described in this paper prior to removal of the reprogramming factors) sustain a low but detectable residual transgene expression (…”
BackgroundInfluentialInduced pluripotent stem cell technology: a decade of progress.
Shi, Y., Inoue, H., Wu, J. C., & Yamanaka, S. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.245 · Cited by 1,525
Immunogenicity of induced pluripotent stem cells
Zhao, T., Zhang, Z.-N., Rong, Z., & Xu, Y. (2011) · Nature · doi:10.1038/nature10135 · Cited by 1,444
“Recent groundbreaking discovery that somatic cells can be reprogrammed into the induced pluripotent stem cells (iPSCs) with defined factors has provided tremendous potential for developing human disease models (Dimos et al., 2008; Ebert et al., 2009; Takahashi and Yamanaka, 2006).”
Emerging trends in regenerative medicine: a scientometric analysis in CiteSpace
Chen, C., Hu, Z., Liu, S., & Tseng, H. (2012) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.674507 · Cited by 1,364
Modelling schizophrenia using human induced pluripotent stem cells
Brennand, K. J., Simone, A., Jou, J., Gelboin-Burkhart, C., Tran, N., Sangar, S., Li, Y., Mu, Y., Chen, G., Yu, D., et al. (2011) · Nature · doi:10.1038/nature09915 · Cited by 1,375
Marchetto, M. C. N., Carromeu, C., Acab, A., Yu, D., Yeo, G. W., Mu, Y., Chen, G., Gage, F. H., & Muotri, A. R. (2010) · Cell · doi:10.1016/j.cell.2010.10.016 · Cited by 1,329
“Although iPSCs have been generated for several neurological diseases (Dimos et al., 2008; Ebert et al., 2009; Hotta et al., 2009; Lee et al., 2009; Park et al., 2008; Soldner et al., 2009), the demonstration Cell 143, 527–539, November 12, 2010 ª2010 Elsevier Inc. 527 of disease-specific…”
BackgroundProbing sporadic and familial Alzheimer’s disease using induced pluripotent stem cells
Israel, M. A., Yuan, S. H., Bardy, C., Reyna, S. M., Mu, Y., Herrera, C., Hefferan, M. P., Van Gorp, S., Nazor, K. L., Boscolo, F. S., et al. (2012) · Nature · doi:10.1038/nature10821 · Cited by 1,253
Patient-Specific Induced Pluripotent Stem-Cell Models for Long-QT Syndrome
Moretti, A., Bellin, M., Welling, A., Jung, C. B., Lam, J. T., Bott-Flügel, L., Dorn, T., Goedel, A., Höhnke, C., Hofmann, F., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908679 · Cited by 1,251
Polo, J. M., Liu, S., Figueroa, M. E., Kulalert, W., Eminli, S., Tan, K. Y., Apostolou, E., Stadtfeld, M., Li, Y., Shioda, T., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1667 · Cited by 1,198
Hu, B.-Y., Weick, J. P., Yu, J., Ma, L.-X., Zhang, X.-Q., Thomson, J. A., & Zhang, S.-C. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0910012107 · Cited by 1,013
“These human iPSCs would overcome the drawbacks of using hESCs and allow for the direct examination of diseased cells for pathological studies and drug screening; this has recently been performed on iPSCs from patients of amyotrophic lateral sclerosis (13), spinal muscular atrophy (14), and familial dysautonomia (15).”
BackgroundSelf-citationShi, Y., Kirwan, P., & Livesey, F. J. (2012) · Nature Protocols · doi:10.1038/nprot.2012.116 · Cited by 972
Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs
Lee, G., Papapetrou, E. P., Kim, H., Chambers, S. M., Tomishima, M. J., Fasano, C. A., Ganat, Y. M., Menon, J., Shimizu, F., Viale, A., et al. (2009) · Nature · doi:10.1038/nature08320 · Cited by 867
Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease
Zuccato, C., Valenza, M., & Cattaneo, E. (2010) · Physiological Reviews · doi:10.1152/physrev.00041.2009 · Cited by 848
“More recently, the induced-Pluripotent Stem (iPS) technology was used for the pathological modeling of Spinal Muscular Atrophy (SMA) (170), and efforts are currently underway to derive iPS cells from HD patients (150, 430).”
MethodInduced pluripotency: history, mechanisms, and applications
Stadtfeld, M., & Hochedlinger, K. (2010) · Genes & Development · doi:10.1101/gad.1963910 · Cited by 829
“Moreover, three promising reports showed that iPSCs derived from patients suffering from the devastating disorders SMA (Ebert et al. 2009), familial dysautonomia (FD) (Lee et al.”
BackgroundInfluentialHuman iPSC-based modeling of late-onset disease via progerin-induced aging
Miller, J. D., Ganat, Y. M., Kishinevsky, S., Bowman, R. L., Liu, B., Tu, E. Y., Mandal, P. K., Vera, E., Shim, J.-W., Kriks, S., et al. (2013) · Cell stem cell · doi:10.1016/j.stem.2013.11.006 · Cited by 777
Direct conversion of human fibroblasts to dopaminergic neurons
Pfisterer, U., Kirkeby, A., Torper, O., Wood, J., Nelander, J., Dufour, A., Björklund, A., Lindvall, O., Jakobsson, J., & Parmar, M. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1105135108 · Cited by 744
Soldner, F., Laganière, J., Cheng, A. W., Hockemeyer, D., Gao, Q., Alagappan, R., Khurana, V., Golbe, L. I., Myers, R. H., Lindquist, S., et al. (2011) · Cell · doi:10.1016/j.cell.2011.06.019 · Cited by 728
Pluripotency and Cellular Reprogramming: Facts, Hypotheses, Unresolved Issues
Hanna, J. H., Saha, K., & Jaenisch, R. (2010) · Cell · doi:10.1016/j.cell.2010.10.008 · Cited by 698
“This is important because for some iPSCs derived from patients, a disease-specific in vitro phenotype has been reported (Carvajal-Vergara et al., 2010; Ebert et al., 2009).”
Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome
Carvajal-Vergara, X., Sevilla, A., D’Souza, S. L., Ang, Y.-S., Schaniel, C., Lee, D.-F., Yang, L., Kaplan, A. D., Adler, E. D., Rozov, R., et al. (2010) · Nature · doi:10.1038/nature09005 · Cited by 690
Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells
Raya, Á., Rodríguez-Pizà, I., Guenechea, G., Vassena, R., Navarro, S., Barrero, M. J., Consiglio, A., Castellà, M., Río, P., Sleep, E., et al. (2009) · Nature · doi:10.1038/nature08129 · Cited by 696
Induced pluripotent stem cells in disease modelling and drug discovery
Rowe, R. G., & Daley, G. Q. (2019) · Nature Reviews Genetics · doi:10.1038/s41576-019-0100-z · Cited by 670
Targeting RNA Foci in iPSC-Derived Motor Neurons from ALS Patients with a C9ORF72 Repeat Expansion
Sareen, D., O’Rourke, J. G., Meera, P., Muhammad, A. K. M. G., Grant, S., Simpkinson, M., Bell, S., Carmona, S., Ornelas, L., Sahabian, A., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3007529 · Cited by 670
Self-citationYamanaka, S. (2009) · Cell · doi:10.1016/j.cell.2009.03.034 · Cited by 659
“Then four groups generated iPS cells from patients with various neurodegenerative diseases—amyotrophic lateral sclerosis (ALS) (Dimos et al., 2008), spinal muscular atrophy (SMA) (Ebert et al., 2009), and Parkinson’s disease (Soldner et al., 2009)—and a variety of genetic diseases with either Mendelian or complex inhe…”
BackgroundInfluentialModeling early retinal development with human embryonic and induced pluripotent stem cells
Meyer, J. S., Shearer, R. L., Capowski, E. E., Wright, L. S., Wallace, K. A., McMillan, E. L., Zhang, S.-C., & Gamm, D. M. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905245106 · Cited by 601
“The potential for iPS cells to generate multiple retinal cell types will aid in the development of in vitro models of human retinal degenerative diseases and stimulate investigation into customized stem cell therapies for patients afflicted by these disorders (34, 35).”
BackgroundModeling familial Alzheimer's disease with induced pluripotent stem cells
Yagi, T., Ito, D., Okada, Y., Akamatsu, W., Nihei, Y., Yoshizaki, T., Yamanaka, S., Okano, H., & Suzuki, N. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr394 · Cited by 599
Modeling inherited metabolic disorders of the liver using human induced pluripotent stem cells
Rashid, S. T., Corbineau, S., Hannan, N., Marciniak, S. J., Miranda, E., Alexander, G., Huang-Doran, I., Griffin, J., Ahrlund-Richter, L., Skepper, J., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci43122 · Cited by 606
Maroof, A. M., Keros, S., Tyson, J. A., Ying, S.-W., Ganat, Y. M., Merkle, F. T., Liu, B., Goulburn, A., Stanley, E. G., Elefanty, A. G., et al. (2013) · Cell Stem Cell · doi:10.1016/j.stem.2013.04.008 · Cited by 596
“, 2008) and spinal muscular atrophy (SMA; Ebert et al., 2009).”
Generation of pluripotent stem cells from patients with type 1 diabetes
Maehr, R., Chen, S., Snitow, M., Ludwig, T., Yagasaki, L., Goland, R., Leibel, R. L., & Melton, D. A. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0906894106 · Cited by 568
Direct reprogramming of mouse fibroblasts to neural progenitors
Kim, J., Efe, J. A., Zhu, S., Talantova, M., Yuan, X., Wang, S., Lipton, S. A., Zhang, K., & Ding, S. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1103113108 · Cited by 572
“, those with Parkinson disease and amyotrophic lateral sclerosis) do not readily recapitulate disease phenotypes when redifferentiated (35, 36), although some patients’ iPSCs with genetic defects show their symptoms (37, 38).”
BackgroundSánchez‐Danés, A., Richaud‐Patin, Y., Carballo‐Carbajal, I., Jiménez‐Delgado, S., Caig, C., Mora, S., Di Guglielmo, C., Ezquerra, M., Patel, B., Giralt, A., et al. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201200215 · Cited by 560
“…iPSC representing a variety of early onset diseases, and shown to display specific features of the disease in vitro (Carvajal-Vergara et al, 2010; Ebert et al, 2009; Ku et al, 2010; Lee et al, 2009; Marchetto et al, 2010; Moretti et al, 2010; Rashid et al, 2010; Raya et al, 2009; Zhang et al,…”
Ring, K. L., Tong, L. M., Balestra, M. E., Javier, R., Andrews-Zwilling, Y., Li, G., Walker, D., Zhang, W. R., Kreitzer, A. C., & Huang, Y. (2012) · Cell Stem Cell · doi:10.1016/j.stem.2012.05.018 · Cited by 538
“, 2008), spinal muscular atrophy (Ebert et al., 2009), Parkinson’s disease (Park et al.”
Screening out irrelevant cell-based models of disease
Horvath, P., Aulner, N., Bickle, M., Davies, A. M., Nery, E. D., Ebner, D., Montoya, M. C., Östling, P., Pietiäinen, V., Price, L. S., et al. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.175 · Cited by 525
Harnessing the potential of induced pluripotent stem cells for regenerative medicine
Wu, S. M., & Hochedlinger, K. (2011) · Nature Cell Biology · doi:10.1038/ncb0511-497 · Cited by 506
“For example, a progressive loss of motor neurons was observed during in vitro differentiation of iPSCs derived from spinal muscular atrophy (SMA) patients, which may reflect the developmental loss of motor neurons seen during this diseas”
Parkinson’s disease induced pluripotent stem cells with triplication of the α-synuclein locus
Devine, M. J., Ryten, M., Vodicka, P., Thomson, A. J., Burdon, T., Houlden, H., Cavaleri, F., Nagano, M., Drummond, N. J., Taanman, J.-W., et al. (2011) · Nature Communications · doi:10.1038/ncomms1453 · Cited by 486
“This approach has already been used to generate cell models for several neurological conditions: amyotrophic lateral sclerosis, sporadic PD, spinal muscular atrophy and familial dysautonomia have all been describe”
MethodThe HD iPSC Consortium (2012) · Cell Stem Cell · doi:10.1016/j.stem.2012.04.027 · Cited by 490
“Neural stem cells (NSCs) were generated from the HD and control iPSC lines by lifting cells into a defined medium with epidermal growth factor (EGF) and fibroblast growth factor-2 (FGF-2), both at 100 ng/ml, as described previously (Ebert et al., 2009).”
MethodInfluentialDerivation of induced pluripotent stem cells from pig somatic cells
Ezashi, T., Telugu, B. P. V. L., Alexenko, A. P., Sachdev, S., Sinha, S., & Roberts, R. M. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905284106 · Cited by 484
Hargus, G., Cooper, O., Deleidi, M., Levy, A., Lee, K., Marlow, E., Yow, A., Soldner, F., Hockemeyer, D., Hallett, P. J., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1010209107 · Cited by 480
“To model disease in vitro, changes have been obtained in patient-derived iPS cells, which could bemodified through the application of chemical compounds during iPS cell differentiation (8, 9) or prevented by gene targeting before iPS cell derivation (4).”
BackgroundInduced pluripotent stem cells — opportunities for disease modelling and drug discovery
Grskovic, M., Javaherian, A., Strulovici, B., & Daley, G. Q. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3577 · Cited by 474
Repair of Acute Myocardial Infarction by Human Stemness Factors Induced Pluripotent Stem Cells
Nelson, T. J., Martinez-Fernandez, A., Yamada, S., Perez-Terzic, C., Ikeda, Y., & Terzic, A. (2009) · Circulation · doi:10.1161/circulationaha.109.865154 · Cited by 471
Meyer, J. S., Howden, S. E., Wallace, K. A., Verhoeven, A. D., Wright, L. S., Capowski, E. E., Pinilla, I., Martin, J. M., Tian, S., Stewart, R., et al. (2011) · Stem Cells · doi:10.1002/stem.674 · Cited by 469
“In addition, patient-derived hiPSC lines have a unique capacity to model human disease [3-6], although the scope of disorders amenable to this form of study is limited [7-9].”
Self-citationZhang, J., Lian, Q., Zhu, G., Zhou, F., Sui, L., Tan, C., Mutalif, R. A., Navasankari, R., Zhang, Y., Tse, H.-F., et al. (2011) · Cell Stem Cell · doi:10.1016/j.stem.2010.12.002 · Cited by 461
“, 2008), spinal muscular atrophy (Ebert et al., 2009), familial dysautonomia (Lee et al.”
BackgroundAdult mice generated from induced pluripotent stem cells
Boland, M. J., Hazen, J. L., Nazor, K. L., Rodriguez, A. R., Gifford, W., Martin, G., Kupriyanov, S., & Baldwin, K. K. (2009) · Nature · doi:10.1038/nature08310 · Cited by 463
iPS Cells Can Support Full-Term Development of Tetraploid Blastocyst-Complemented Embryos
Kang, L., Wang, J., Zhang, Y., Kou, Z., & Gao, S. (2009) · Cell Stem Cell · doi:10.1016/j.stem.2009.07.001 · Cited by 457
“…and the generation of iPSCs from individual patients has raised hopes for treating many degenerative and genetic diseases (Dimos et al., 2008; Ebert et al., 2009; Hanna et al., 2007; Park et al., 2008; Soldner et al., 2009; Takahashi et al., 2007; Takahashi and Yamanaka, 2006; Wernig et al.,…”
BackgroundGeneration and expansion of highly pure motor neuron progenitors from human pluripotent stem cells
Du, Z.-W., Chen, H., Liu, H., Lu, J., Qian, K., Huang, C.-L., Zhong, X., Fan, F., & Zhang, S.-C. (2015) · Nature Communications · doi:10.1038/ncomms7626 · Cited by 457
“The above disease iPSCs have been generated from patients and attempts have been made to identify disease-related phenotypes and to dissect out the underlying mechanisms before embarking on drug discovery 7–10 .”
Induced pluripotent stem cells: the new patient?
Bellin, M., Marchetto, M. C., Gage, F. H., & Mummery, C. L. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3448 · Cited by 431
Osakada, F., Jin, Z.-B., Hirami, Y., Ikeda, H., Danjyo, T., Watanabe, K., Sasai, Y., & Takahashi, M. (2009) · Journal of Cell Science · doi:10.1242/jcs.050393 · Cited by 426
“Additionally, patient-specific iPS cell-derived retinal cells will facilitate the development of transplantation therapies without immune rejection, and promote an improved understanding of disease pathogenesis (Dimos et al., 2008; Ebert et al., 2009; Park et al., 2008).”
BackgroundSingh, V. K., Kalsan, M., Kumar, N., Saini, A., & Chandra, R. (2015) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2015.00002 · Cited by 416
Generation of Induced Pluripotent Stem Cell Lines from Tibetan Miniature Pig
Esteban, M. A., Xu, J., Yang, J., Peng, M., Qin, D., Li, W., Jiang, Z., Chen, J., Deng, K., Zhong, M., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.008938 · Cited by 418
Technical Challenges in Using Human Induced Pluripotent Stem Cells to Model Disease
Saha, K., & Jaenisch, R. (2009) · Cell Stem Cell · doi:10.1016/j.stem.2009.11.009 · Cited by 411
“Small-Molecule and Protein Therapeutic Discovery Recent hiPS cellular disease models already have lead to smallmolecule candidates for treating familial dysautonomia (Lee et al., 2009) and SMA type I (Ebert et al., 2009).”
BackgroundMethodInfluentialYe, Z., Zhan, H., Mali, P., Dowey, S., Williams, D. M., Jang, Y.-Y., Dang, C. V., Spivak, J. L., Moliterno, A. R., & Cheng, L. (2009) · Blood · doi:10.1182/blood-2009-04-217406 · Cited by 399
Lamba, D. A., McUsic, A., Hirata, R. K., Wang, P.-R., Russell, D., & Reh, T. A. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008763 · Cited by 394
“Recent studies have shown that motor neurons derived from iPS cells from patients with spinal muscular atrophy have been shown to have selective motor neuron death [26].”
ResultSeibler, P., Graziotto, J., Jeong, H., Simunovic, F., Klein, C., & Krainc, D. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.4441-10.2011 · Cited by 378
“, 2008), spinal muscular atrophy (SMA) (Ebert et al., 2009), and familial dysautonomia (FD) (Lee et al.”
BackgroundInfluentialDirected Differentiation of Human-Induced Pluripotent Stem Cells Generates Active Motor Neurons
Karumbayaram, S., Novitch, B. G., Patterson, M., Umbach, J. A., Richter, L., Lindgren, A., Conway, A. E., Clark, A. T., Goldman, S. A., Plath, K., et al. (2009) · Stem Cells · doi:10.1002/stem.31 · Cited by 374
“The generation of motor neurons from human iPS cells isolated from patients harboring ALS and SMA mutations has recently been described, though the electrophysiological activity of these motor neurons was not assessed [8,9].”
Therapies for rare diseases: therapeutic modalities, progress and challenges ahead
Tambuyzer, E., Vandendriessche, B., Austin, C. P., Brooks, P. J., Larsson, K., Miller Needleman, K. I., Valentine, J., Davies, K., Groft, S. C., Preti, R., et al. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0049-9 · Cited by 357
Progress toward the clinical application of patient-specific pluripotent stem cells
Kiskinis, E., & Eggan, K. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40553 · Cited by 339
Bilican, B., Serio, A., Barmada, S. J., Nishimura, A. L., Sullivan, G. J., Carrasco, M., Phatnani, H. P., Puddifoot, C. A., Story, D., Fletcher, J., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1202922109 · Cited by 328
Almeida, S., Gascon, E., Tran, H., Chou, H. J., Gendron, T. F., DeGroot, S., Tapper, A. R., Sellier, C., Charlet-Berguerand, N., Karydas, A., et al. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1149-y · Cited by 321
“Indeed, iPSC models of several neurodegenerative diseases have been established [3, 15, 16, 20, 21, 24, 35, 43].”
BackgroundNotch Signaling in the Regulation of Stem Cell Self-Renewal and Differentiation
Liu, J., Sato, C., Cerletti, M., & Wagers, A. (2010) · Current Topics in Developmental Biology · doi:10.1016/s0070-2153(10)92012-7 · Cited by 311
Isolation of human iPS cells using EOS lentiviral vectors to select for pluripotency
Hotta, A., Cheung, A. Y. L., Farra, N., Vijayaragavan, K., Séguin, C. A., Draper, J. S., Pasceri, P., Maksakova, I. A., Mager, D. L., Rossant, J., et al. (2009) · Nature Methods · doi:10.1038/nmeth.1325 · Cited by 300
“This makes them useful reporters to more efficiently isolate accurately reprogrammed iPS cell lines from knockout or transgenic mice, which may be difficult to cross with Nanog - or Oct4 -reporter mice, and from human biopsies to model disease in vitro”
BackgroundIn vitro Models of Neurodegenerative Diseases
Slanzi, A., Iannoto, G., Rossi, B., Zenaro, E., & Constantin, G. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00328 · Cited by 290
Oki, K., Tatarishvili, J., Wood, J., Koch, P., Wattananit, S., Mine, Y., Monni, E., Tornero, D., Ahlenius, H., Ladewig, J., et al. (2012) · Stem Cells · doi:10.1002/stem.1104 · Cited by 293
“, dopaminergic neurons [19, 20] and motorneurons [21, 22].”
Itoh, M., Kiuru, M., Cairo, M. S., & Christiano, A. M. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1100332108 · Cited by 282
“It has recently been shown that PS-iPSCs from a patient with spinal muscular atrophy (SMA) can be generated and differentiated into motor neurons (4).”
BackgroundFemale Human iPSCs Retain an Inactive X Chromosome
Tchieu, J., Kuoy, E., Chin, M. H., Trinh, H., Patterson, M., Sherman, S. P., Aimiuwu, O., Lindgren, A., Hakimian, S., Zack, J. A., et al. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.06.024 · Cited by 279
“To date, hiPSCs have been generated from patients with a variety of genetic diseases including ALS, SMA, Parkinson disease, Huntington disease, juvenile-onset, type 1 diabetes mellitus, and Down syndrome (Dimos et al., 2008; Ebert et al., 2009; Park et al., 2008), and should also be invaluable for studies of X-linked…”
BackgroundCheung, A. Y. L., Horvath, L. M., Grafodatskaya, D., Pasceri, P., Weksberg, R., Hotta, A., Carrel, L., & Ellis, J. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr093 · Cited by 271
“D3–4-hiPS cells were fully reprogrammed, as retroviral transgenes were largely silenced and have simultaneously reactivated the endogenous loci of the reprogramming factors similar to previously published patient-specific hiPS cell lines (29,31,32) (Fig.”
BackgroundResultJung, Y., Bauer, G., & Nolta, J. A. (2012) · STEM CELLS · doi:10.1002/stem.727 · Cited by 270
Induced pluripotent stem cells in medicine and biology
Takahashi, K., & Yamanaka, S. (2013) · Development · doi:10.1242/dev.092551 · Cited by 265
“Disease-specific iPSC lines were first reported by two groups in 2008 (Dimos et al., 2008; Park et al., 2008), and in vitro reconstruction of the disease state was first successful in the case of spinal muscular atrophy (SMA) (Ebert et al., 2009; Ebert et al., 2012).”
BackgroundStepwise differentiation of pluripotent stem cells into retinal cells
Osakada, F., Ikeda, H., Sasai, Y., & Takahashi, M. (2009) · Nature Protocols · doi:10.1038/nprot.2009.51 · Cited by 269
“In addition, induced pluripotent stem cell technology will likely allow us to make progress on in vitro modeling and patient-specific therap”
BackgroundCurrent status of pluripotent stem cells: moving the first therapies to the clinic
Kimbrel, E. A., & Lanza, R. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4738 · Cited by 261
Mica, Y., Lee, G., Chambers, S. M., Tomishima, M. J., & Studer, L. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.03.025 · Cited by 257
“, 2007) has been successfully applied to model human diseases (Dimos et al., 2008; Ebert et al., 2009; Park et al., 2008b), including disorders of the NC such as familial dysautonomia (Lee et al.”
MethodInvestigating human disease using stem cell models
Sterneckert, J. L., Reinhardt, P., & Schöler, H. R. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3764 · Cited by 249
Accelerated High-Yield Generation of Limb-Innervating Motor Neurons from Human Stem Cells
Amoroso, M. W., Croft, G. F., Williams, D. J., O'Keeffe, S., Carrasco, M. A., Davis, A. R., Roybon, L., Oakley, D. H., Maniatis, T., Henderson, C. E., et al. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.0906-12.2013 · Cited by 248
Dravet syndrome patient‐derived neurons suggest a novel epilepsy mechanism
Liu, Y., Lopez‐Santiago, L. F., Yuan, Y., Jones, J. M., Zhang, H., O'Malley, H. A., Patino, G. A., O'Brien, J. E., Rusconi, R., Gupta, A., et al. (2013) · Annals of Neurology · doi:10.1002/ana.23897 · Cited by 243
Immune Influence on Adult Neural Stem Cell Regulation and Function
Carpentier, P. A., & Palmer, T. D. (2009) · Neuron · doi:10.1016/j.neuron.2009.08.038 · Cited by 234
“iPSC lines have been created from patients with neurological diseases such as PD, amyotrophic lateral sclerosis (ALS), and spinal muscular atrophy (SMA) (Dimos et al., 2008; Ebert et al., 2009; Soldner et al., 2009).”
E-Cadherin-Mediated Cell–Cell Contact Is Critical for Induced Pluripotent Stem Cell Generation
Chen, T., Yuan, D., Wei, B., Jiang, J., Kang, J., Ling, K., Gu, Y., Li, J., Xiao, L., & Pei, G. (2010) · Stem Cells · doi:10.1002/stem.456 · Cited by 234
Zou, J., Sweeney, C. L., Chou, B.-K., Choi, U., Pan, J., Wang, H., Dowey, S. N., Cheng, L., & Malech, H. L. (2011) · Blood · doi:10.1182/blood-2010-12-328161 · Cited by 236
Vatine, G. D., Al-Ahmad, A., Barriga, B. K., Svendsen, S., Salim, A., Garcia, L., Garcia, V. J., Ho, R., Yucer, N., Qian, T., et al. (2017) · Cell Stem Cell · doi:10.1016/j.stem.2017.04.002 · Cited by 233
“Technologies to reprogram adult cells back to a pluripotent state, termed induced pluripotent stem cells (iPSCs) (Takahashi and Yamanaka, 2006; Yu et al., 2007), provide an unprecedented platform for studying human genetic disorders (Ebert et al., 2009; Mattis et al., 2015).”
BackgroundSelf-citationiPS cell technologies: significance and applications to CNS regeneration and disease
Okano, H., & Yamanaka, S. (2014) · Molecular Brain · doi:10.1186/1756-6606-7-22 · Cited by 233
“A variety of disease-specific iPS cells have been used to study nervous system diseases, including amyotrophic lateral sclerosis (ALS) [46-48], spinal muscular atrophy [49], spinobulbar muscular atrophy [50], Friedreich’s ataxia [51], Alzheimer’s disease (AD) [52-54], PD [55-58], Huntington’s disease [59,60], Machado-…”
BackgroundInduced Pluripotent Stem Cells: Problems and Advantages when Applying them in Regenerative Medicine
Medvedev, S. P., Shevchenko, A. I., & Zakian, S. M. (2010) · Acta Naturae · doi:10.32607/20758251-2010-2-2-18-27 · Cited by 232
Juopperi, T. A., Kim, W. R., Chiang, C.-H., Yu, H., Margolis, R. L., Ross, C. A., Ming, G.-L., & Song, H. (2012) · Molecular Brain · doi:10.1186/1756-6606-5-17 · Cited by 225
“Successful modeling of neurological disorders using iPSC technology have been reported, but mainly with neurodevelopmental disorders, such as spinal muscular atrophy [56], Rett syndrome [57] and familial dysautonomia [58].”
In vitro pharmacologic testing using human induced pluripotent stem cell-derived cardiomyocytes
Tanaka, T., Tohyama, S., Murata, M., Nomura, F., Kaneko, T., Chen, H., Hattori, F., Egashira, T., Seki, T., Ohno, Y., et al. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.05.073 · Cited by 226
Lee, G., Ramirez, C. N., Kim, H., Zeltner, N., Liu, B., Radu, C., Bhinder, B., Kim, Y. J., Choi, I. Y., Mukherjee-Clavin, B., et al. (2012) · Nature Biotechnology · doi:10.1038/nbt.2435 · Cited by 225
Constitutive secretion of tau protein by an unconventional mechanism
Chai, X., Dage, J. L., & Citron, M. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.05.021 · Cited by 224
Induced Pluripotent Stem Cells as a Disease Modeling and Drug Screening Platform
Ebert, A. D., Liang, P., & Wu, J. C. (2012) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e318247f642 · Cited by 222
Self-citationThe Use of Induced Pluripotent Stem Cells in Drug Development
Inoue, H., & Yamanaka, S. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.38 · Cited by 221
Si-Tayeb, K., Noto, F. K., Sepac, A., Sedlic, F., Bosnjak, Z. J., Lough, J. W., & Duncan, S. A. (2010) · BMC Developmental Biology · doi:10.1186/1471-213x-10-81 · Cited by 220
“If human iPS cells are generated from specific patients they offer an opportunity to study the molecular mechanism underlying the pathogenesis [1,2].”
BackgroundLab-Specific Gene Expression Signatures in Pluripotent Stem Cells
Newman, A. M., & Cooper, J. B. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.06.016 · Cited by 217
“All nodes are numbered by cluster label and are co blue = Yu et al., 2009, GSE15176 data set; yellow-green = Ebert et al., 2009, GSE1 et al., 2007, GSE9709 data set; red = Park et al., 2008, GSE9832 data set; oran GSE16093 data set; purple = Chin et al., 2009, GSE16654 data set).”
BackgroundNeuronal maturation defect in induced pluripotent stem cells from patients with Rett syndrome
Kim, K.-Y., Hysolli, E., & Park, I.-H. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018979108 · Cited by 216
Sodium channel gene family: epilepsy mutations, gene interactions and modifier effects
Meisler, M. H., O’Brien, J. E., & Sharkey, L. M. (2010) · The Journal of Physiology · doi:10.1113/jphysiol.2010.188482 · Cited by 217
“Recent papers describe the generation of neurons from patients with spinal motor atrophy (Ebert et al. 2009), amyotrophic lateral sclerosis (ALS) (Dimos et al.”
BackgroundDarras, B. T. (2015) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2015.03.010 · Cited by 201
“The incidence of SMA has been estimated at 1 in 6000 to 11,000 live births4–7 or approximately 7.8 to 10 per 100,000 live births8–10 and at 4.1 per 100,000 live births for type I SMA.8 The estimated panethnic disease frequency is approximately 1 in 11,000.7 The carrier frequency for mutations in the SMN1 gene has been…”
InfluentialSingh, R., Shen, W., Kuai, D., Martin, J. M., Guo, X., Smith, M. A., Perez, E. T., Phillips, M. J., Simonett, J. M., Wallace, K. A., et al. (2013) · Human Molecular Genetics · doi:10.1093/hmg/dds469 · Cited by 213
Uzel, S. G. M., Platt, R. J., Subramanian, V., Pearl, T. M., Rowlands, C. J., Chan, V., Boyer, L. A., So, P. T. C., & Kamm, R. D. (2016) · Science Advances · doi:10.1126/sciadv.1501429 · Cited by 213
Choi, K.-D., Vodyanik, M. A., & Slukvin, I. I. (2009) · Journal of Clinical Investigation · doi:10.1172/jci38591 · Cited by 212
Mitne-Neto, M., Machado-Costa, M., Marchetto, M. C. N., Bengtson, M. H., Joazeiro, C. A., Tsuda, H., Bellen, H. J., Silva, H. C. A., Oliveira, A. S. B., Lazar, M., et al. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr284 · Cited by 214
“Similar to other studies (48,49), our results suggest that mutations that cause MNDs are unlikely to affect cell reprogramming.”
BackgroundResultSpinal muscular atrophy: mechanisms and therapeutic strategies
Lorson, C. L., Rindt, H., & Shababi, M. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq147 · Cited by 209
“iPS cells from an SMA patient can be differentiated in culture into motor neurons expressing specific transcription factors and markers such as choline acetyltransferase (72).”
Self-citationStem cell cultivation in bioreactors
Rodrigues, C. A. V., Fernandes, T. G., Diogo, M. M., da Silva, C. L., & Cabral, J. M. S. (2011) · Biotechnology Advances · doi:10.1016/j.biotechadv.2011.06.009 · Cited by 210
“…is of great interest, not only due to the ethical concerns surrounding human ESCs, but also because it allows the derivation of patient-specific pluripotent stem cell lines (Ebert et al., 2009; Soldner et al., 2009), thus generating cells suitable for clinical and pharmacological applications.”
BackgroundSpliceosome integrity is defective in the motor neuron diseases ALS and SMA
Tsuiji, H., Iguchi, Y., Furuya, A., Kataoka, A., Hatsuta, H., Atsuta, N., Tanaka, F., Hashizume, Y., Akatsu, H., Murayama, S., et al. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201202303 · Cited by 208
“These results indicate that TDP-43, FUS and SMN (Ebert et al, 2009) are all required for formation of nuclear Gems.”
Diseases in a dish: modeling human genetic disorders using induced pluripotent cells
Tiscornia, G., Vivas, E. L., & Belmonte, J. C. I. (2011) · Nature Medicine · doi:10.1038/nm.2504 · Cited by 206
Metadata
- Authors
- Ebert, A. D., Yu, J., Rose, F. F., Mattis, V. B., Lorson, C. L., Thomson, J. A., & Svendsen, C. N.
- Affiliations
- University of Wisconsin–Madison (US)
- University of Missouri (US)
- Corresponding author
- Ebert, Allison D.
- Svendsen, Clive N.
- Venue
- Nature
- Published
- 2008-12-21
- Volume
- 457
- Issue
- 7227
- Pages
- 277-280
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC2659408
- OpenAlex
- W2145492799
- Cited by
- 1,441
- References
- 42
- Citations by year
- 2026: 10 · 2025: 15 · 2024: 28 · 2023: 31 · 2022: 36 · 2021: 33 · 2020: 46 · 2019: 54 · 2018: 53 · 2017: 60 · 2016: 85 · 2015: 109 · 2014: 112 · 2013: 145 · 2012: 199
- FWCI
- 58.08
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institute on Aging (T32AG027566)
- National Institute of General Medical Sciences (T32GM008396)
- National Institute of Neurological Disorders and Stroke (R01 NS41584, P01NS057778, R01NS041584)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (R01HD054413)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Keywords
- spinal muscular atrophy, induced pluripotent stem cells, motor neurons, SMN1, SMN2, dermal fibroblasts, disease modeling, neural progenitor cells, drug screening, inherited neurological diseases, Huntington's disease
- MeSH terms
- Cell Differentiation, Cell Separation, Cells, Cultured, Child, Female, Fibroblasts, Gene Expression Regulation, Humans, Male, Models, Biological, Motor Neurons, Muscular Atrophy, Spinal, Skin, Cell Lineage, Pluripotent Stem Cells, Survival of Motor Neuron 1 Protein, Cellular Reprogramming
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.